Medicine price transparency and confidential managed-entry agreements in Europe
Findings from the Euripid survey
Bibliographic Data
| ID | 21467482 |
|---|---|
| Authors | Pierluigi Russo (0000-0003-4881-5703, Italian Medicines Agency, corresponding author), Angelica Carletto (0000-0002-2094-1946, Italian Medicines Agency), Gergely Németh (0000-0002-1590-2133), Claudia Habl (0000-0002-0999-6401, Gesundheit Österreich) |
| Year | 2021 |
| Volume | 125 |
| Issue | 9 |
| Pages | 1140-1145 |
| Publication date | 2021-09-01 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Health Policy (JOURNAL) |
| Journal identifiers | ISSN: 0168-8510 • E-ISSN: 1872-6054 |
| Publisher | Elsevier BV (PUBLISHER) |
| DOI | 10.1016/j.healthpol.2021.06.008 |
| PMID | 34253396 |
| OpenAlex | W3177361552 |
| Language | EN |
| Citations received | 3 |
| References cited | 18 |
Pricing of pharmaceuticals is an all-time challenge for healthcare systems. Often public payers agree with companies on confidential managed-entry agreements (MEAs) that, e.g. foresee discounts under specific circumstances. The EURIPID Executive Committee surveyed 22 European countries, who all reported the use of confidential agreements between pharmaceutical companies and public payers, confirming that the actual prices paid are typically lower than the published list price. In 68% of the countries, the confidentiality of MEAs is required by non-disclosure clauses between companies and public payers. In some countries (27%) this is even backed up by a specific law. Our study identified legal constraints for the sharing of information on actual prices and confidential agreements among European countries and consequently restrictions in transparency. In conclusion, the EURIPID survey findings suggest that the current possibility to improve the medicines' price transparency across countries is limited and the issue probably requires international institutional engagement, at least to coordinate initiatives toward a greater collaboration among member states
Business · Confidentiality · Economics · Political science · Public disclosure · Public economics · Health Systems, Economic Evaluations, Quality of Life · Law · Pharmaceutical Economics and Policy · Pharmaceutical industry and healthcare · Accounting
Lessons learned from the Canadian Fabry Disease Initiative for future risk-sharing and managed access agreements for pharmaceutical and advanced therapies in Canada
Price regulation and competition among on-patent anticancer drugs in Italy
Why is the pharmaceutical industry investing in targeted therapies? The emergence of “premium pharma”
| Citations per year | 1.5 |
|---|---|
| Citation span | 2024 - 2026 (3) |
| Highly cited | No |